HUMAN RELEVANT MODEL ENABLES BETTER TRANSLATION TO PHARMACOLOGY AND THE CLINIC
April 17, 2019 | (10AM)
USA (United States of America)
Current drug development strategies are very expensive and lead to high drug attrition rates. One major reason for low success rates is the lack of predictive preclinical models for efficacy testing. The availability of induced pluripotent stem cell (hiPSC) technologies holds great promise to bring human biology to drug discovery but is still compromised by problems related to scalability, biological relevance, robustness and costs.